Compare Natera Inc. Common Stock (NTRA) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Palo Alto Networks Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Palo Alto Networks Inc trades at $367.96 (market cap $324.77B). The key difference: Palo Alto Networks Inc is far larger — about 5.7× Natera Inc. Common Stock's market cap, and Palo Alto Networks Inc is more actively traded (3,473,783 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Palo Alto Networks Inc for 82 Days on average.
| NTRA | PANW | |
|---|---|---|
Market Cap | $57.03B | $324.77B |
Volume | 1,131,157 | 3,473,783 |
Sector | Health | Technology |
52-Week High | $425.64 | $419.91 |
52-Week Low | $179.42 | $141.67 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $56.18B | $324.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Palo Alto Networks (PANW) trades at $375.04, down 7.13% over the past day but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive sentiment from 64 buy ratings. Recent earnings beats and robust revenue growth to $9.22B in 2025 highlight fundamental strength, though valuation ratios remain elevated with a P/E of 992.58. The company's AI-driven security platform and continuous defense services are key growth drivers, positioning it well in the cybersecurity sector.
Outlook: PANW's AI integration and platformization strategy support long-term growth, with a consensus price target of $400.05 offering ~6.7% upside. Risks include premium valuation, rising costs, and competitive pressures. Investors should weigh strong fundamentals against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
